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Background: Rituximab is commonly used for systemic lupus erythematosus (SLE)
but secondary non-depletion and non-response (2NDNR) associated with anti-drug
antibodies is a notable problem with repeat rituximab cycles. Other B cell-targeted
therapies include other anti-CD20 monoclonal antibodies or belimumab.
Objective: To compare efficacy of switching to alternative anti-CD20 agents vs.
belimumab in SLE patients with 2NDNR to rituximab.
Methods: One hundred and twenty five patients received rituximab and had evaluable
data. 77/125 received repeat rituximab cycles. Of these, 14/77 (18%) had 2NDNR.
8/14 patients were switched to belimumab (CD20-to-belimumab group) and 6/14
patients were switched to an alternative humanised anti-CD20 agent (CD20-to-CD20
group, ocrelizumab n = 3, ofatumumab n = 2, obinutuzumab n = 1). Efficacy was
assessed using the BILAG-2004, SLEDAI-2K, SRI-4, and daily prednisolone requirement
at baseline and 6 months.
Results: In the CD20-to-belimumab group, only one patient achieved an SRI-4 and
2/8 patients had new/worsening BILAG-2004 grade A for lupus nephritis. There was
no improvement in SLEDAI-2K; median (IQR) was 11.0 (9.5–14.8) at baseline and
10 (9.5–15.5) at 6 months. Median (IQR) prednisolone dose increased from 7.5mg
(4.4–12.5) to 10mg (6.3–10). In the CD20-to-CD20 group, all 6 patients achieved an
SRI-4. Median (IQR) SLEDAI-2K improved from 16.0 (10.3–24.0) at baseline to 5.0
(2.5–6.0) at 6 months. Median (IQR) prednisolone dose decreased from 15mg (15–15)
to 10.5 mg (5.3–15.0).
Conclusion: This is the first assessment of belimumab’s efficacy in a post-rituximab
population. Our data suggests that patients with 2NDNR to rituximab, which constituted
11% of all patients initiated on this drug, should be switched within the same biologic
class to another anti-CD20 agent.
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INTRODUCTION
Rituximab, a chimeric monoclonal antibody (mAb) is commonly
used off-label for the treatment of antibody positive systemic
lupus erythematosus (SLE) in patients with severely active
disease (including renal manifestations) despite conventional
immunosuppressants such as mycophenolate mofetil and
cyclophosphamide (1). Although two large phase III randomised
controlled trials EXPLORER (non-renal) and LUNAR (renal)
failed to meet their primary end points, rituximab appears to
be effective in a large number of single-centre open label series
(2–4), multi-centre registries (1, 5) and a systematic review of
off-label use (6). We previously reported that clinical response
to rituximab was better if complete B cell depletion, as measured
using highly sensitive flow cytometry [HSFC (7)], was achieved
(8). However, in patients with good initial response to a first
cycle of rituximab, we found a substantial rate of secondary non-
depletion and non-response (2NDNR). We previously defined
this as a phenomenon whereby SLE patients who initially
responded well to rituximab with B-cell depletion, subsequently
experienced; a severe infusion reaction > 24 h during the second
infusion of a cycle; failed to completely deplete B-cells; and did
not clinically respond during repeat cycles. 2NDNR is associated
with anti-rituximab antibodies. Since these patients often had
severe disease resistant to other therapies, determining the best
follow-on therapy in this situation is crucial.
It is logical to continue to target B cells in these patients given
their prior good response to rituximab. There are two potential
strategies. First, switching to an alternative anti-CD20 agent,
particularly humanised (type I mAb: ocrelizumab, ofatumumab
or type II mAb: obinutuzumab), has been reported with good
clinical outcomes for the type I anti-CD20 mAbs (8–10) as well
as in vitro for obinutuzumab (11). None of these anti-CD20
mAbs are currently licensed for use in SLE. Second, switching
to belimumab as currently the only biologic agent licensed for
treating SLE. Belimumab targets B cells indirectly via B cell
activating factor (BAFF) inhibition. BAFF is not only a potent B
cell activator, it also plays an important role in B cell proliferation
and differentiation (12). Although it is licenced for treating
antibody positive SLE with a high degree of disease activity
(excluding active renal and neuro-psychiatric complications), its
evidence for efficacy is mainly in biologic-naïve patients (13, 14).
Neither option has previously been assessed in the context of
2NDNR to rituximab.
BAFF levels are known to significantly increase after B cell
depletion, and this may assist in the survival of new B cells
emigrating from bone marrow. BAFF levels have also been
associated with relapse after rituximab (15). Based on these
findings, several trials are in progress using a combination of
rituximab and belimumab (16, 17). However, this treatment
regimen and trial population are clearly distinct from the
rituximab 2NDNR problem.
The objective of this study was to report the comparative
efficacy of switching to either (i) belimumab, or (ii) alternative,
humanised anti-CD20 agents in SLE patients with prior 2NDNR
to rituximab. We hypothesised that both of these B cell targeted
agents would have higher response rates in 2NDNR patients than
for SLE patients without previous 2NDNR. However, our results
showed a marked difference in their efficacy in this population.
METHODS
Patients and Design
A prospective observational study was conducted of all patients
with moderate to severe SLE [with at least 1× British Isles Lupus
Assessment Group (BILAG)-2004 grade A or 2 x BILAG-2004
grade Bs] who were treated with rituximab in Leeds between
January 2004 and October 2019. Inclusion criteria were (1) age
≥ 18 years old; (2) fulfilling the revised 1997 American College
of Rheumatology classification for SLE (18) and (3) at least
6 months follow-up post-rituximab and post-rituximab switch
following a 2NDNR (defined below). Total follow up time on
each therapy was calculated from the date of therapy initiation
until the date of therapy discontinuation / death / last update of
data in January 2020.
Rituximab Therapy and 2NDNR
Rituximab (MabThera) was administered to patients if they
had moderate to severe SLE despite prior therapy with either
mycophenolate mofetil or cyclophosphamide, or with toxicity
to these agents, in line with the NHS England criteria (19).
Rituximab was administered as 2 × 1000mg at weeks 0
and 2, each preceded by 100mg methylprednisolone. Patients
received repeat cycles of the same dose of rituximab if they
had a clinical relapse, defined by at least 1 x new BILAG-
2004 B, following an initial response at 6 months. In this
cohort, we previously reported that 14% of patients with SLE
who had previously depleted and responded well to rituximab,
subsequently experienced (1) a severe infusion reaction > 24 h
during the second infusion of a cycle, (2) failure to deplete
CD20+ B cells (naïve andmemory) and (3) clinical non-response
during repeat cycles. We called this secondary non-depletion and
non-response (2NDNR) (8). This phenomenon has also been
reported by other groups (20).
Rituximab to Belimumab Switch
(CD20-to-Belimumab Group)
Treatment for 8 patients with 2NDNR to rituximab was switched
to belimumab. Belimumab was administered using its licensed
dose of 10 mg/kg at weeks 0, 2, 4 then every 4 weeks. It was
discontinued in patients with non-response or if their condition
worsened, requiring other therapies.
Rituximab to Alternative Anti-CD20 mAb
Switch (CD20-to-CD20 Group)
For 6 patients with 2NDNR, therapy was switched to a
humanised anti-CD20 agent. This was chosen based on
availability (compassionate supply from Roche, or individual
funding from the NHS England). Three patients were treated
with ocrelizumab 2 × 1000mg at weeks 0 and 2, each preceded
by 100mg methylprednisolone; for 2 patients we treated with
ofatumumab 2 × 700mg at weeks 0 and 2, each preceded
by 100mg methylprednisolone; and 1 patient was treated with
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obinutuzumab 2 × 1000mg at weeks 0 and 2, each preceded by
100 mg methylprednisolone.
Treatment choice was determined by availability and funding
rather than clinical status. Patients were treated with alternative
anti-CD20 agents before the NICE approval and when these
agents were available. This depended on compassionate
supply from manufacturers (ocrelizumab), individual funding
applications until no longer available (ofatumumab), and
funding by the hospital trust (obinutuzumab). From the date of
the NICE approval for belimumab, patients received belimumab
if they met NICE criteria.
Clinical Outcomes
Data were collected as part of the Leeds Connective Tissue
Disease and Vasculitis (CONVAS) observational study. Baseline
characteristics including demographics, disease activity, previous
and concomitant immunosuppressant and daily prednisolone
use were collected. Treatment efficacy was assessed using the
BILAG-2004 (21), SLE Disease Activity Index version 2000
[SLEDAI-2K (22)], and daily prednisolone requirement at
baseline and 6 months after the follow-on therapy.
BILAG-2004 responses at 6 months were determined as
follows: (1) major clinical response (MCR) = improvement
of all domains rated A/B to grade C/better and no A/B flare
between baseline and 6 months; (2) partial clinical response
(PCR) = maximum of 1 domain with a persistent grade B with
improvement in all other domains and no A or B flare; or (3)
no clinical response (NCR) = those not meeting the criteria for
major or partial clinical response. Global BILAG-2004 score was
calculated as follows: grade A= 12, grade B= 8, grade C= 1, and
grades D and E= 0 (23).
SLE Responder Index (SRI-4) was defined by a 4-point
improvement in the SLEDAI-2K with no worsening in the
BILAG-2004 or in the physicians’ global assessment (24).
Laboratory Assessments
Peripheral blood B-cell subsets (naïve, memory B-cells and
plasmablasts) were measured using HSFC as previously
described (7) at baseline and 6 weeks after treatment with
rituximab or alternative anti-CD20 agents without knowledge
of clinical status other than time since therapy. Complete
B-cell depletion was defined as counts < 0.0001 × 109/L and
repopulation as ≥ 0.0001 × 109/L. Anti-dsDNA titres and ENA
profile (anti-Ro, -La, -Sm, -Scl-70, -Jo-1, -RNP, -Sm/RNP, -
Ribosomal P, -Chromatin) were measured using ImmunoCAPTM
chemiluminescent immunoassay by Thermo Fischer Scientific
prior to July 2012 and Bioplex 2200 Immunoassay (after July
2012). Complement levels (C3 and C4) (normal range for
C3: 0.75–1.65 g/L and for C4: 0.14–0.54 g/L) and total serum
immunoglobulin titres were measured by nephelometry. All
immunological tests above were analysed at an accredited
NHS laboratory.
Ethics Approval
This observational study was approved by the Leeds (East)
Research Ethics Committee (REC), 10/H1306/88 and conducted
in compliance with the Declaration of Helsinki. All patients
gave written informed consent. The off-label use of rituximab,
ofatumumab, ocrelizumab and obinutuzumab were all approved
by the Leeds Teaching Hospitals NHS Trust Drug and
Therapeutic Committee.
Statistical Analyses
Descriptive statistics were summarised using median with
interquartile range (IQR) for continuous variables and
proportion for categorical variables. Continuous variables
were compared using either Student’s t-tests, Mann-Whitney’s
test or Kruskall-Wallis test depending on data type and
distribution. All statistical analysis was performed using IBM
SPSS Statistics v21.0 (IBM Corp, Armonk, New York, USA) and
Graph Pad Prism V.6.01 for Windows.
RESULTS
Demographics of Patients With 2NDNR to
Rituximab
One hundred and twenty five patients with SLE received
rituximab in Leeds over the 15 years follow-up and had evaluable
data at 6 months. Of these, 100/125 (80%) had an initial
BILAG-2004 response (MCR and PCR). 77/125 (62%) patients
suffered a relapse and required repeat cycles of rituximab. Of
these, 61/77 (79%) patients maintained BILAG-2004 response,
2/77 (3%) had secondary inefficacy, and 14/77 (18%) developed
2NDNR either in the second cycle (n = 10/77; 13%) or
the third cycle (n = 3/40; 8%). Baseline characteristics of
the 14 patients with 2NDNR to rituximab are summarised
in Table 1. Patients who were switched to alternative anti-
CD20 agents (CD20-to-CD20 group) were younger at the
time of drug initiation, had shorter disease duration, lower
number of previous oral immunosuppressants when compared
to those who were switched to belimumab (CD20-to-belimumab
group). However, the dose of concomitant oral prednisolone,
median SLEDAI-2K scores, and the proportion of patients on
concomitant anti-malarial and immunosuppressants (IS) were
comparatively higher in the CD20-to-CD20 group.
Clinical Outcomes of the
CD20-to-Belimumab Group
Eight patients received belimumab after rituximab. All were
female with a median (IQR) age at the time of drug initiation
of 44.0 years (31.5–56.8). Reasons for failure of rituximab in this
subgroup were: (i) primary non-response (never responded) =
1/8; and (ii) 2NDNR = 7/8. At belimumab baseline, 6/8 patients
had positive anti-dsDNA and low complement levels in line with
data predicting better response to belimumab and the current
UK National Institute for Health and Care Excellence (NICE)
guidance (25, 26). The other two patients were treated prior to
the publication of this guidance.
At 6 months post-belimumab, only one patient achieved an
SRI-4. However, belimumab was discontinued for this patient
at the 6-month time point due to recurrent chest and urinary
tract infections. Another 2/8 patients had a 4-point reduction
in SLEDAI-2K (22→18 and 14→10) but failed to achieve SRI-4
due to one having new BILAG-2004 activity in cardiorespiratory
Frontiers in Medicine | www.frontiersin.org 3 August 2020 | Volume 7 | Article 498
Hassan et al. Biologic Sequencing in 2NDNR in SLE
TABLE 1 | Baseline characteristics.
Characteristic CD20-to-Belimumab
Group (n = 8)
CD20-to-CD20
Group (n = 6)
Age (years), Median (IQR) 44.0 (31.5–56.8) 28.0 (23.3–35.0)
Female:Male 8:0 6:0
Ethnicity, n (%)
Caucasian
5/8 (63) 1/6 (17)
Afro Caribbean 3/8 (37) 5/6 (83)
Disease duration at drug initiation
(years), Median (IQR)
18.0 (12.8–20.0) 6.5 (6.0–8.5)
Previous Cyclophosphamide, n (%) 3/8 (37) 1/6 (17)
Number of previous oral
immunosuppressants*,
Median (IQR)
3.0 (2.5–5.0) 1.5 (1.0–2.8)
Prednisolone dose (mg),
Median (IQR)
7.5 (4.4–12.5) 15.0 (15.0–15.0)
Concomitant antimalarial, n (%) 4/8 (50) 4/6 (67)
Concomitant IS*, n (%) 4/8 (50) 5/6 (83)
SLEDAI-2K,
Median (IQR)
11.0 (9.5–14.8) 16.0 (10.3–24.0)
BILAG-2004 A/B**, n (%)
General
1/8 (13) 3/6 (50)
Mucocutaneous 6/8 (75) 3/6 (50)
Neuropsychiatric 1/8 (13) 2/6 (33)
Musculoskeletal 6/8 (75) 3/6 (50)
Cardiorespiratory 1/8 (13) 0/6 (0)
Renal 1/8 (13) 4/6 (67)
Haematological 1/8 (13) 1/6 (17)
*concomitant immunosuppressant (IS) = Azathioprine, Mepacrine, Methotrexate,
Mycophenolate Mofetil or Tacrolimus.
**no patient had activity in gastroenterological or ophthalmic domains of BILAG-2004 so
these data not shown.
domain (Grade E→B) and worsening in general domain (Grade
C→B), whilst the other had worsening of both mucocutaneous
and renal domains (Grade B→A). A complete breakdown of
BILAG-2004 domain scores at baseline and 6 months are shown
in Table 2.
There was no significant improvement in the SLEDAI-
2K post-belimumab; median (IQR) at baseline and 6 months
were 11.0 (9.5–14.8) and 10 (9.5–15.5), respectively; p = 0.629
(Figure 1A). There was no improvement in the Global BILAG-
2004 score post-belimumab; median (IQR) at baseline and 6
months were 21.5 (20.0–22.8) and 19.0 (15.3–22.8), respectively;
p = 0.366 (Figure 1B). Median (IQR) prednisolone dose had
increased from 7.5mg (4.4–12.5) at baseline to 10mg (6.3–10)
at 6 months; p= 0.654 (Figure 1C).
Notably, there were two new episodes of lupus nephritis
during belimumab therapy (1 = relapse with Class III nephritis
and 1 = de novo Class II and V nephritis). Treatment for both
patients was switched to intravenous cyclophosphamide therapy.
Total follow up time on therapy in this group was 9.9 patient-
years. 4/8 patients continued therapy for longer than 6 months
and they all received increased doses of immunosuppressant
and prednisolone. Of these, 1/4 patient had initial BILAG-2004
PCR but developed flare of lupus nephritis and stopped at 11
months; 1/4 patient did not meet either an SRI-4 or BILAG-2004
response at 6 months but had BILAG-2004 PCR at 9 months and
discontinued therapy at 24 months due to secondary inefficacy;
1/4 patient had two lengthy interruptions to therapy due to
unrelated surgical procedures leading to cessation of belimumab
at 24 months; and 1/4 patient remains on belimumab at 3 years
but still not in clinical remission despite requiring escalation of
concomitant oral immunosuppressants and prednisolone.
Immunological Outcomes of the
CD20-to-Belimumab Group
Of 6/8 patients with increased anti-dsDNA titre at belimumab
baseline, none achieved normalisation of anti-dsDNA titre at
6 months. Furthermore, anti-dsDNA titre did not significantly
improve post-belimumab; median (IQR) at baseline and at 6
months were 56 IU/mL (21–132) and 27.5 IU/mL (14.8–104.3),
respectively; p= 0.356 (Figure 2A).
For complement C3 level, median (IQR) at baseline and at
6 months were 1.07 g/L (0.84–1.17) and 1.03 g/L (0.88–1.21),
respectively; p = 0.948 (Figure 2B). 1/8 patient with low level
at baseline did not improve post-belimumab. For complement
C4 level, median (IQR) at baseline and at 6 months were 0.11
g/L (0.08–0.12) and 0.12 g/L (0.09–0.17), respectively; p = 0.231
(Figure 2C). 6/8 patients had low level at baseline. Of these, only
1/6 had normalisation of C4 level at 6 months post-belimumab.
C3 and/or C4 levels which were normal at baseline (n = 2),
remained within normal range at 6 months post-belimumab.
Clinical Outcomes of the CD20-to-CD20
Group
Following 2NDNR to rituximab, treatment for 6 patients was
switched to humanised anti-CD20 mAbs (3 = ocrelizumab, 2 =
ofatumumab, and 1= obinutuzumab). All 6 patients were female
with a median (IQR) age at the time of drug initiation of 28.0
years (23.3–35.0).
Total follow up time on therapy in this group was 31.8 patient-
years. Six weeks after treatment with the alternative anti-CD20
agent, complete B cell depletion was achieved in 5/6 patients,
while the remaining one had substantially reduced total B cell
counts (0.0016× 109/L).
At 6 months post-switch to alternative anti-CD20 agents, all
patients achieved an SRI-4. The median (IQR) SLEDAI-2K score
had improved from 16.0 (10.3–24.0) at baseline to 5.0 (2.5–6.0)
at 6 months; p = 0.019 (Figure 1A). The Global BILAG-2004
score significantly improved from 22.5 (18.0–36.8) at baseline to
2.5 (2.0–3.0) at 6 months; p = 0.009 (Figure 1B). This is also
reflected in the BILAG-2004 response, which was MCR for 5/6
patients and PCR for the remainder 1/6 patient, vs. no MCR in
the CD20-to-Belimumab group. In fact, 3/8 patients in the CD20-
to-Belimumab group had a worsening of BILAG-2004 response.
A complete breakdown of BILAG-2004 domains at baseline and
6 months post-alternative anti-CD20 mAbs switch are shown
in Table 2. Furthermore, median (IQR) prednisolone dose had
decreased from 15mg (15–15) at baseline to 10.5mg (5.3–15.0)
at 6 months; p= 0.033 (Figure 1C).
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TABLE 2 | BILAG-2004 scores.
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CD20-to-Belimumab Group
1 Bel E A E B E E C 21 E B E B E E C 17 PCR
2 Bel E B E E E E C 9 E B E E E E C 9 NCR
3 Bel A C E C D E B 22 D C E C E A B 22 NCR
4 Bel D B E B D B C 25 D A E D D A C 25 NCR
5 Bel D B E B D E C 17 D B E B D E C 17 NCR
6 Bel C B D A A E D 33 C C D B D E D 10 PCR
7 Bel E E B A D E C 21 E E B A D E C 21 NCR
8 Bel C B E A E E C 22 B B E C B E C 26 NCR
CD20-to-CD20 Group
9 Ocr B A E B D A C 41 D C E D D D C 2 MCR
10 Ocr B E E D E A C 21 D E E D E D C 1 MCR
11 Ocr E E B B E E C 17 E E D C E E C 2 MCR
12 Ofa E E E E E A A 24 E E E E E B C 9 PCR
13 Ofa B A B B E A C 49 D C D D E C C 3 MCR
14 Obi D A D C E D C 14 D C D C E D C 3 MCR
Ocr, Ocrelizumab; Ofa, Ofatumumab; Obi, Obinutuzumab; MCR, major clinical response; PCR, partial clinical response; NCR, no clinical response.
FIGURE 1 | SLEDAI-2K, Global BILAG-2004, and Daily prednisolone dose. Clinical efficacy assessments for the CD20-to-belimumab and the CD20-to-CD20 groups.
Each figure shows the pre- and post-treatment results for the (A) SLEDAI-2K, (B) total BILAG score, and (C) daily oral prednisolone requirements in the
CD20-to-CD20 group compared to the CD20-to-belimumab group. Points represent median and error bars denote interquartile range. BL, Baseline; 6 mo, 6 months.
Immunological Outcomes of the
CD20-to-CD20 Group
In all 6 patients, the anti-dsDNA titres had reduced at 6 months,
however none normalised; median (IQR) at baseline and at 6
months were 301.0 IU/ml (137.5–342.3) and 121.5 IU/ml (74.8–
259.0), respectively; p = 0.107 (Figure 2A). For complement
C3 and C4 levels, 4/6 had low levels for both at baseline.
Of these, 3/4 had normalisation of the C3 and C4 levels at
6 months (Figures 2B,C). Those C3 or C4 levels which were
normal at baseline (n = 2), remained within normal range at 6
months post-alternative anti-CD20 mAbs switch. Median (IQR)
for complement C3 level at baseline and at 6 months were
0.53 g/L (0.45–0.89) and 1.18 g/L (0.91–1.21), respectively; p =
0.087. For complement C4 level at baseline and at 6 months,
median (IQR) were 0.06 g/L (0.05–0.13) and 0.17 g/L (0.15–0.18),
respectively; p= 0.004.
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FIGURE 2 | Anti-dsDNA titres and complement levels. Immunological tests for the CD20-to-belimumab and the CD20-to-CD20 groups. Each figure shows the pre-
and post-treatment for the (A) anti-dsDNA titres; (B) complement C3 level and (C) complement C4 level. Points represent median and error bars denote interquartile
range. The dotted red lines represent lower limit of the normal values of the tests. BL, Baseline; 6 mo, 6 months.
DISCUSSION
In this study, we report the first evidence on biologic switching
in SLE, suggesting an important difference in response after
rituximab. These data highlight the importance of appropriate
biologic sequencing in this growing resistant subgroup.
Many potential therapeutic targets have been explored for
SLE. The most prominent target the B cell pathway directly.
Most pharmacological agents targeting B cells either deplete them
(rituximab, ocrelizumab, ofatumumab, and obinutuzumab); or
inhibit BAFF (belimumab, tabalumab, atacicept). Non-B cell
targets are diverse and include type I interferon (IFN-I) (27),
interleukin (IL) 12/23, CTLA4-CD28 co-stimulation and the
Janus kinase/signal transducers and activators of transcription
(JAK-STAT) pathway. These agents may still impact on B cells,
but only indirectly.
The diversity of these potential targets raises the question of
the most appropriate follow-on therapy in patients who either
fail to respond to their first biologic or, lose an initial good
response (2NDNR). The answer to this question depends on our
understanding of the mechanism for inadequate response.
For most manifestations of SLE, we showed that a key
determinant of rituximab response is the degree of B cell
depletion achieved with therapy (8). This implies that
these clinical manifestations are B cell-dependent. Some
manifestations of SLE appear to be non-B cell mediated. We
showed that most discoid lupus erythematosus and some
subacute cutaneous lupus erythematosus lesions either did not
respond, worsened or initiated during rituximab therapy despite
complete peripheral B cell depletion (28).
Belimumab may also be more effective in a subgroup of
SLE patients in whom B cells have a more dominant role. In
randomised clinical trials, the difference in response between
belimumab and placebo is twice as large in patients with B cell
biomarkers (i.e., raised anti-dsDNA titres and low complement
levels) (29).
Thus, for patients initially responding well to rituximab (i.e.,
have proven B cell-dependent manifestations) but subsequently
develop pharmacodynamic resistance (2NDNR), switching to
any other B cell targeted therapy would appear to be an
appropriate strategy. We therefore expected a higher SRI-4
response rate than the ∼55% of unselected SLE patients who
responded in the pivotal trials of belimumab (12, 13, 30) given the
resultant raised BAFF levels following successful depletion of B-
cells.We also expected a high response rate to an alternative B cell
depleting therapy, provided that depletion could be adequately
restored. Surprisingly, we found that the SRI-4 response rate to
belimumab was markedly worse in our study than in its trials,
especially noting the new episodes of lupus nephritis.
These results may reveal potential complexities of therapeutic
BAFF inhibition. After rituximab, there is a marked elevation of
serum BAFF; up to 10-fold normal levels (31). Simultaneously,
there is a marked shift in B cell dynamics with sustained
reduction of naïve B cells that bear the BAFF-R receptor.
Thus, there are relatively greater proportions of memory B
cells and plasmablasts that express tumour necrosis factor
receptor superfamily member 13b (TACI) and B cell maturation
antigen (BCMA) receptors instead. These memory B cells and
plasmablasts also bind APRIL (3). In particular, TACI signalling
may have more complex effects on B cells than the BAFF-R
signalling that predominates in rituximab-naïve SLE patients
(32). Given these changes, it may therefore be expected that
the effects of BAFF blockade in this situation might differ from
the general SLE population in which the drug was evaluated in
phase III trials.
In contrast, the effectiveness of alternative anti-CD20 agents
in patients with 2NDNR to rituximab is entirely consistent with
our hypothesis and the correlations we have reported between
the degree of B cell depletion and clinical response. Anti-drug
antibodies are more likely to occur against chimaeric mAbs.
Regular cycles of rituximab may theoretically prevent their
development, but the long treatment intervals required for some
SLE patients, as well as the underlying propensity for B cell
activity and antibody formation in SLE may account for their
higher frequency in SLE compared to other diseases in which
rituximab is used. The alternative anti-CD20 agents used in this
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study were humanised or fully human. There may be other
differences between anti-CD20 agents that affect the efficacy
of depletion in SLE, which may be particularly important for
obinutuzumab (33).
These results may not affect the use of belimumab in SLE
patients in general, nor the rationale for the various rituximab-
belimumab combination strategies in clinical trials (34). Neither
do they provide a comparison of the efficacy of these agents
in their more typical patient populations. However, this study
emphasises the importance of gathering data on belimumab
in real world settings and deeper understanding of the BAFF
pathway in SLE.
This study has some limitations. First, the sample size was
small to definitively confirm the efficacy of the two strategies
used in patients with 2NDNR to rituximab. These findings need
to be validated in larger patient cohorts. However, the size of
the difference seems large since only one patient in the CD20-
to-belimumab group achieved the SRI-4 compared to all of the
patients treated with alternative anti-CD20 agents. Second, this
study was non-randomised. There was an imbalance in some of
the baseline clinical characteristics, particularly patients in the
CD20-to-CD20 group who had worse SLE (i.e., higher SLEDAI-
2K and higher concomitant daily prednisolone). However, this
group still showed better response to therapy compared with the
CD20-to-belimumab group. There were some patients with renal
involvement at baseline in the CD20-to-CD20 group and not the
belimumab group. However, since we observed new episodes of
nephritis in the CD20-to-belimumab group, it does not seem
promising to further investigate this line of therapy in more
severe patients. Our patients were all recruited from the same
population and assessed in the same way in a single centre with
marked differences in response rates. Lastly, concomitant therapy
with immunosuppressant were used in 83% of the patients, thus
the overall efficacy could not be attributed to the alternative anti-
CD20 agents alone. Nevertheless, our long-term follow-up of
a large cohort of rituximab-treated patients is one of the best
sources of data available for these more complex questions. It
is unlikely that randomised trials will ever be completed for this
question. In the absence of randomised trials, and with a clinically
important problem, it is appropriate to use the best case series
evidence available.
In conclusion, 2NDNR is an increasingly common problem
in SLE patients treated with rituximab, often with severe disease.
For these patients, our data suggest biologic therapy should
be switched within the same class; i.e., to another anti-CD20
agent. This study demonstrates the importance of stratification of
therapy in SLE, based on an understanding of the determinants
of response.
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